Longevity Peptides
FOXO4-DRI
Peptide
Premium FOXO4-DRI peptide designed for advanced longevity, wellness optimization and modern biohacking-focused protocols in Dubai and across the UAE.
From AED 150.00
FOXO4-DRI Overview
FOXO4-DRI is a peptide antagonist designed to disrupt the interaction between FOXO4 and p53, two proteins that work together to keep senescent cells alive. Research published on PubMed (2026) documents that FOXO4-DRI promotes selective apoptosis of senescent endothelial cells and improves vascular function in aged animal models.
It has gained attention in longevity and bio-optimization communities for its association with cellular aging research and modern senolytic peptide exploration. A study published on NIH/PMC found FOXO4-DRI selectively removes senescent cells without significantly affecting non-senescent cell populations.
At Elite Peptide Core, FOXO4-DRI is positioned within our premium Longevity Peptides collection for customers looking for a refined and professional peptide experience backed by clean branding, secure checkout and discreet delivery.
Why Customers Explore FOXO4-DRI
One of the most discussed senolytic peptides in longevity research communities.
Longevity Optimization
Frequently explored in advanced longevity discussions. PubMed research (2026) documents its studied role in delaying vascular aging via selective senescent cell clearance.
Biohacking Interest
Popular among wellness-focused users interested in modern senotherapy and cellular optimization strategies.
Cellular Research
NIH/PMC-published research shows FOXO4-DRI selectively targets senescent cells by disrupting the FOXO4-p53 interaction without affecting healthy cell populations.
Advanced Research Interest
Commonly discussed in longevity-focused peptide communities and scientific interest groups exploring senolytic compounds.
Available Strengths
FOXO4-DRI is available in two strength options. Select your preferred variant on the product page before checkout.
Premium FOXO4-DRI for Longevity & Wellness
FOXO4-DRI has become increasingly recognized within longevity and advanced wellness discussions due to its association with cellular aging research and bio-optimization protocols. A 2026 study on PubMed demonstrated that FOXO4-DRI prevents FOXO4 from binding to P53, facilitating senescent cell apoptosis via the p53/BCL-2/Caspase-3 signaling pathway.
Our FOXO4-DRI peptide is part of the wider Longevity Peptides collection, where customers can explore additional peptides commonly discussed in healthy aging, advanced wellness and performance-focused longevity routines.
Customers interested in complete longevity-focused peptide systems may also explore our peptide stack collections, where FOXO4-DRI is commonly paired with other longevity-oriented peptides such as Thymosin Alpha-1, Epitalon and Dihexa.
The Research Background
Research published on NIH/PMC found that injection of FOXO4-DRI in both naturally aged and progeroid model mice effectively suppressed aortic aging and improved aortic function, confirming its role in vascular senescence modulation.
A separate NIH/PMC study on senolytic peptides demonstrated that FOXO4-DRI removed more than half of senescent cells in expanded human chondrocyte cultures without significantly affecting healthy non-senescent cell populations, illustrating its selective mechanism.
This research background positions FOXO4-DRI as one of the more rigorously studied senolytic peptide compounds within the longevity and cellular wellness category.
Customer Reviews
Rated 4.8/5 based on verified customer reviews.
"The website experience felt very premium and organized. Product packaging and delivery updates were excellent."
Dubai, UAE"One of the cleanest peptide websites I have ordered from. Checkout process was smooth and professional."
Abu Dhabi, UAE"Good experience overall. Product presentation and delivery quality were impressive."
Sharjah, UAE